GlassScriptPhysician profile
Vikas S Desai
NPI 1659333102
$1,608.46
in general payments reported to CMS, 2019-2025
17 companies · $590 in 2025
The $590 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25.00 · 2021: $59.89 · 2023: $315 · 2024: $619 · 2025: $590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,524.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,523.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $238.20 | 2021-2025 | |
| Pfizer INC. | $223.50 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $187.75 | 2024-2025 | Camzyos, Eliquis |
| Amgen INC. | $157.87 | 2024-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $140.74 | 2023-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $138.37 | 2021-2024 | Breztri |
| Heartflow, INC. | $113.16 | 2023-2025 | Ffrct |
| Alnylam Pharmaceuticals INC. | $102.92 | 2024-2025 | Onpattro, Amvuttra |
| Novo Nordisk INC | $57.82 | 2019-2024 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $50.55 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.41 | 2025 | Jardiance |
| Irhythm Technologies, INC. | $37.21 | 2024 | Zio Xt Patch, Zio Monitor |
| Glaxosmithkline, LLC. | $32.10 | 2023 | Shingrix, Arexvy |
| Philips North America LLC | $23.08 | 2024 | (Ck7) Extended Holter |
| Vital Connect, INC | $20.89 | 2025 | Vitalpatch Rtm |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $20.73 | 2025 | Verquvo, Lagevrio, Capvaxive |
| Exact Sciences Corporation | $20.16 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikas Desai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.